Bionoxx

Focus: Bionoxx is an oncology-focused biotechnology company based in Korea specializing in tumor-targeting antigens. The company is in early-stage development with a focused pipeline in solid tumors.

Oncology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Bionoxx

AI assessmentNot Hiring

No open roles listed right now. Follow Bionoxx to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

3 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

OTS-412

Treatment-Refractory Solid Tumors

Phase 1

Clinical Trials (1)

NCT07190833A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients (South Korea)

Phase 1

Help build intelligence for Bionoxx

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage oncology platform with potential to establish novel tumor-targeting approaches if OTS-412 demonstrates clinical benefit
Korea-based location offers potential exposure to Asia-Pacific biotech ecosystem and emerging markets
Opportunity to build foundational capabilities at a pre-commercial stage company with focused therapeutic strategy

Watch Out For

No active job openings reported despite being an active clinical-stage company, suggesting minimal near-term hiring
Extremely early pipeline (Phase 1 only) with no published data, high probability of failure, and no clear path to revenue
No financial data available, limiting visibility into funding runway, cash position, or company stability

Generated by Claude from Bionoxx's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

OTS-412

Treatment-Refractory Solid Tumors

Phase 1

Clinical Trials (1)

NCT07170592A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients

Phase 1

OTS-412

Healthy Volunteer

Phase 1

Clinical Trials (1)

NCT07302945A Single-volunteer Study of Immune Response Following OTS-412 Vaccinia Virus Systemic Injection(Self-experiment)

Phase 1

Open Jobs (0)

No open positions listed yet.

Interview Prep Quick Facts

Portfolio: 3 clinical trials

Top TAs: Oncology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Oncology

2 pipeline

Marketed

Pipeline